These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 25151018)
1. Corticosteroids and prostate cancer: friend or foe? Geynisman DM; Szmulewitz RZ; Plimack ER Eur Urol; 2015 May; 67(5):874-5. PubMed ID: 25151018 [No Abstract] [Full Text] [Related]
2. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037 [TBL] [Abstract][Full Text] [Related]
3. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review]. Ma H; Zhu G; Wan B; Wu PJ; Wang JY Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489 [TBL] [Abstract][Full Text] [Related]
4. Corticosteroids in the management of prostate cancer: a critical review. Ndibe C; Wang CG; Sonpavde G Curr Treat Options Oncol; 2015 Feb; 16(2):6. PubMed ID: 25762121 [TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE; Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341 [TBL] [Abstract][Full Text] [Related]
7. Is dexamethasone a better partner for abiraterone than prednisolone? Dizdar O Oncologist; 2015 May; 20(5):e13. PubMed ID: 25888271 [TBL] [Abstract][Full Text] [Related]
8. Making progress on progression in metastatic prostate cancer. Armstrong AJ; Halabi S J Clin Oncol; 2015 Apr; 33(12):1322-4. PubMed ID: 25667271 [No Abstract] [Full Text] [Related]
16. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Teply BA; Luber B; Denmeade SR; Antonarakis ES Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146 [TBL] [Abstract][Full Text] [Related]
17. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266 [TBL] [Abstract][Full Text] [Related]
18. Abiraterone-induced rhabdomyolysis: A case report. Moore DC; Moore A J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407 [TBL] [Abstract][Full Text] [Related]
19. [Recruiting participants - study of therapy of CRPC]. Aktuelle Urol; 2014 Sep; 45(5):354-5. PubMed ID: 25275687 [No Abstract] [Full Text] [Related]
20. Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer. Petrioli R; Francini E; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Roviello G Anticancer Res; 2015 May; 35(5):3097-102. PubMed ID: 25964601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]